SCHEMBL11913684

SCHEMBL11913684

O=C(CCN1C(=O)/C(=C/c2cccc(Br)c2)SC1=S)Nc1ccc(O)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDX3X O00571 3/20 0.84
▸ MEN1 O00255 11/20 0.75
▸ KMT2A Q03164 11/20 0.75
▸ HSPD1 P10809 1/20 0.75
▸ HSPE1 P61604 1/20 0.75
▸ MAPT P10636 7/20 0.74
▸ SMN1; SMN2 Q16637 4/20 0.71
▸ LMNA P02545 3/20 0.71
▸ ALDH1A1 P00352 3/20 0.71
▸ HTT P42858 3/20 0.71
▸ MAPK1 P28482 3/20 0.71
▸ TDP1 Q9NUW8 2/20 0.71
▸ GAA P10253 2/20 0.71
▸ ATM Q13315 1/20 0.71
▸ L3MBTL1 Q9Y468 1/20 0.71
▸ NPC1 O15118 2/20 0.68
▸ RAB9A P51151 1/20 0.68
▸ POLB P06746 2/20 0.67
▸ PAX8 Q06710 2/20 0.67
▸ ALPL P05186 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11913683 0.91 DDX3X (1.00) DDX3XMEN1KMT2AHSPD1HSPE1
SCHEMBL12008752 0.91 KMT2A (0.82) DDX3XMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL17319558 0.90 DDX3X (0.74) DDX3XMEN1KMT2AHSPD1HSPE1
SCHEMBL11918194 0.86 DDX3X (0.90) DDX3XMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL12008751 0.86 DDX3X (0.80) DDX3XMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL11899368 0.86 DDX3X (1.00) DDX3XMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL11899366 0.86 DDX3X (1.00) DDX3XMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL11899367 0.86 DDX3X (1.00) DDX3XMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL17319559 0.85 KMT2A (0.72) DDX3XMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL11913686 0.84 DDX3X (0.80) DDX3XMEN1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206412-B2 Thioxothiazolidine inhibitors COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2015-12-08 — — US disclosed
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF UNIVERSITÀ DEGLI STUDI DI SIENA (IT) 2012-08-09 — — US disclosed
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF UNIVERSITÀ DEGLI STUDI DI SIENA (IT) 2012-08-09 — — US disclosed
WO-2011039735-A2 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2011-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF DDX3X, DDX21, DDX39B DDX3X 1/4885MEN1 1855/4885KMT2A 2610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback